Start free

PolicyChanges tracks payer policy changes for medical practices and tells you what to do before they take effect.

Create a free accountPolicy Monitoring is free. No card required.
← Back to list
Blue Cross & Blue Shield of MississippiAll Plans · Billing Codes · Medical Policy · Urology, Oncology, RadiologyMedium impact

Magnetic Resonance Imaging-Targeted Biopsy of the Prostate

Effective date
Jan 1, 2026
Identified
Jun 20, 2026

Summary

BCBSMS policy L.7.01.448 states that magnetic resonance imaging-targeted biopsy of the prostate may be considered medically necessary for diagnosis and active surveillance of prostate cancer. Effective 01/01/2026, the Code Reference section adds new CPT codes 55708, 55710, 55711, 55712, 55713, 55714 and 55715 for MRI-fusion and in-bore CT- or MRI-guided prostate biopsy.

Get alerts when payers change rules like this one

We check Blue Cross & Blue Shield of Mississippi and other payers every day and email you when a change matches your specialty and state.

Get Blue Cross & Blue Shield of Mississippi alertsPolicy Monitoring is free. No card required.

What to do

Action · 2 steps
01Already effective 2026-01-01: Billing team should bill CPT 55708, 55710, 55711, 55712, 55713, 55714 and 55715 only when the procedure is performed according to the policy, and should document that the biopsy is for diagnosis or active surveillance of prostate cancer, because BCBSMS makes no payment for services not documented to be medically necessary.
02Check the current applicability of these codes before billing them.

Codes mentioned

557085571055711557125571355714557155589977021C61D07.5D40.0Z85.46

Original notice

Magnetic Resonance Imaging-Targeted Biopsy of the Prostate
bcbsms.com · Always check the source before changing claims.
View original ↗

Related changes

See all Blue Cross & Blue Shield of Mississippi changes →
Whole Gland Cryoablation of Prostate CancerMediumNo effective date · Medical PolicyImmunohistochemistry for Microscopic Evaluation of Prostate BiopsyMediumNo effective date · Medical PolicySaturation Biopsy for Diagnosis, Staging, and Management of Prostate CancerMediumNo effective date · Medical PolicyGermline and Somatic Biomarker Testing (Including Liquid Biopsy) for Targeted Treatment in Prostate Cancer (BRCA1/2, Homologous Recombination Repair Gene Alterations, NTRK Gene Fusion)MediumNo effective date · Medical PolicyBrowse every Blue Cross & Blue Shield of Mississippi change in the policy list

Related policy hubs

Blue Cross & Blue Shield of Mississippi policiesUrologyOncologyRadiologyCode 55708Code 55710Code 55711Code 55712Code 55713Code 55714Code 55715Code 55899Code 77021Code C61Code D07.5Code D40.0Code Z85.46

Summaries are AI-assisted. Always confirm against the original payer notice.

What is PolicyChanges

One workspace for payer rules, prior auth, coding and compliance

Medical practices use PolicyChanges to catch payer changes before they cause denials. Every change is summarized in plain English, with the codes involved, the date it takes effect and what to do.

Policy MonitoringPayer policy, prior auth and coding changes, filtered to your saved searchesOIG ScreeningStaff and vendors screened every month against OIG LEIE, SAM.gov and state Medicaid listsPrior Auth LookupKnow if a service needs prior authorization before you schedule itCredentialing TrackerLicenses, CAQH, Medicare revalidation and payer enrollments, with reminders before anything lapsesCompliance CenterKeep your HIPAA program documented and ready to show
Start freePolicy Monitoring is free. No card required.
Get alerts for changes like thisPolicy Monitoring is free. No card required.Create a free account